Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters

Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1... ORIGINAL INVESTIGATION Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters Writing Committee for the CASCADE Collaboration* Background: To estimate the clinical benefit of highly Results: Of 9455 patients with 52 268 person-years of active antiretroviral therapy (HAART) initiation vs de- follow-up, 812 (8.6%) developed AIDS and 544 (5.8%) ferral in a given month in patients with CD4 cell counts died. In CD4 cell count strata of 200 to 349, 350 to 499, less than 800/µL. and 500 to 799/µL, HAART initiation was associated with adjusted hazard ratios (95% CIs) for AIDS/death of 0.59 Methods: In this observational cohort study of human (0.43-0.81), 0.75 (0.49-1.14), and 1.10 (0.67-1.79), re- immunodeficiency virus type 1 seroconverters from spectively. In the analysis of all-cause mortality, HAART CASCADE (Concerted Action on SeroConversion to AIDS initiation was associated with adjusted hazard ratios (95% and Death in Europe), we constructed monthly sequen- CIs) of 0.71 (0.44-1.15), 0.51 (0.33-0.80), and 1.02 (0.49- tial nested subcohorts between January 1996 and May 2.12), respectively. Numbers needed to treat (95% CIs) 2009, including all eligible HAART-naive, AIDS-free in- to prevent 1 AIDS event or death within 3 years were 21 dividuals with a CD4 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters

JAMA Internal Medicine , Volume 171 (17) – Sep 26, 2011

Loading next page...
 
/lp/american-medical-association/timing-of-haart-initiation-and-clinical-outcomes-in-human-6rl31PW35i
Publisher
American Medical Association
Copyright
Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2011.401
pmid
21949165
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters Writing Committee for the CASCADE Collaboration* Background: To estimate the clinical benefit of highly Results: Of 9455 patients with 52 268 person-years of active antiretroviral therapy (HAART) initiation vs de- follow-up, 812 (8.6%) developed AIDS and 544 (5.8%) ferral in a given month in patients with CD4 cell counts died. In CD4 cell count strata of 200 to 349, 350 to 499, less than 800/µL. and 500 to 799/µL, HAART initiation was associated with adjusted hazard ratios (95% CIs) for AIDS/death of 0.59 Methods: In this observational cohort study of human (0.43-0.81), 0.75 (0.49-1.14), and 1.10 (0.67-1.79), re- immunodeficiency virus type 1 seroconverters from spectively. In the analysis of all-cause mortality, HAART CASCADE (Concerted Action on SeroConversion to AIDS initiation was associated with adjusted hazard ratios (95% and Death in Europe), we constructed monthly sequen- CIs) of 0.71 (0.44-1.15), 0.51 (0.33-0.80), and 1.02 (0.49- tial nested subcohorts between January 1996 and May 2.12), respectively. Numbers needed to treat (95% CIs) 2009, including all eligible HAART-naive, AIDS-free in- to prevent 1 AIDS event or death within 3 years were 21 dividuals with a CD4

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Sep 26, 2011

References